ArticleCirculation reports2026
Combined Prognostic Performance of the CADILLAC Risk Score and C-Reactive Protein/Albumin Ratio in Acute Myocardial Infarction.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality, so accurate early risk stratification is essential for predicting adverse events. We investigated whether combining the Creactive protein/albumin ratio (CAR) with the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) risk score was associated with an increased risk of 1-year major adverse cardiac events (MACE), and assessed its efficacy in the risk stratification of patients with AMI undergoing primary percutaneous coronary intervention (PCI). Methods and Results: In total, 554 patients were enrolled. The rate of 1-year MACE was 10.5%. Both the CADILLAC risk category and CAR tertile were independent predictors of 1-year MACE, after adjustment for covariates (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.34-2.92, P=0.001; HR 1.65, 95% CI 1.14-2.37, P=0.007, respectively). Compared to patients with a low CADILLAC risk score and a low CAR tertile, those with a high CADILLAC risk score and a high CAR tertile had the highest 1-year MACE (adjusted HR 8.13, 95% CI 1.88-35.2, P=0.005). Adding CAR to a model that combined the CADILLAC risk score with the baseline factors significantly improved the prediction of 1-year MACE. Conclusions: Combining the CAR with the CADILLAC risk score significantly contributed to predicting 1-year MACE in patients with AMI undergoing primary PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.